that already offer needle exchange or methadone services.
Community pharmacists have the potential to screen at-risk groups for
hepatitis C and could play a key role in helping to improve liver
disease services in primary care, according to the conclusions of a
commission set up to investigate the impact of the disease.
Writing in The Lancet (online, 27 November 2014),
the group of leading doctors and medical scientists who made up the
commission argue that screening for hepatitis C in primary care is
People at risk of the disease could be screened in community
pharmacies that already offer needle exchange or methadone services,
suggests the group, led by Roger Williams, director of the institute of
hepatology at Foundation for Liver Research, London.